Cofactor Biosynthetic Pathways in Mycobacterium tuberculosis as Potential Drug Targets
Current Respiratory Medicine Reviews,
Shilpika Pandey, Sarthak Gaur, Neha Topno, Sidharth Chopra and Arunava DasguptaAffiliation:
Division of Microbiology, CSIR-Central Drug Research Institute, B.S. 10/1, Sector 10, Janakipuram Extension, Sitapur Road, Lucknow - 226031, Uttar Pardesh, India.
AbstractThere are many chemotherapeutic interventions available for tuberculosis (TB) and are in use for more than five decades, but still there is an urgent need for novel drugs against new targets due to emergence of resistant strains. Moreover, the ability of Mycobacterium tuberculosis (Mtb) to survive within granulomas in a non-replicating latent stage prolongs the course of drug dose and hence increases the severity of the disease. The significant rerouting of metabolism is one of the key processes that help mycobacteria adapt to the hostile environment of host granuloma. In this review, we are focusing on some of the cofactor biosynthetic pathways of Mycobacterium tuberculosis and their utilization as drug targets.
FAD, Mtb, NAD, Pantothenate, iron, vitamin.
Purchase Online Order Reprints Order Eprints Rights and Permissions